Related by context. All words. (Click for frequent words.) 72 NSABP B 70 BCIRG 69 HCV RESPOND 2 68 Folfox 68 SABCS 66 RECORD1 66 HCV SPRINT 65 RE LY ® 65 Stenting Trial CREST 65 ABCSG 65 CLARITY TIMI 65 EURIDIS 65 Xelox 64 Randomized Phase III 64 Val HeFT 64 Hormone Refractory Prostate Cancer 64 relapsed MM 64 ExTRACT TIMI 64 ELOXATIN 64 Taxotere ® 64 unfractionated heparin UFH 64 Aggressive Reduction 64 Oral Fingolimod 64 Cardiovascular Outcomes 64 CAMMS# 64 Prostate Cancer Prevention 64 IMPACT DCM 64 assessing T DM1 64 Arch Intern Med 64 HYVET 64 LUX Lung 63 Gynecologic Oncology Group 63 ATACAND 63 Carotid Revascularization Endarterectomy vs. 63 Genitourinary Cancers Symposium 63 recurrent malignant glioma 63 Fulvestrant 63 CALGB 63 galiximab 63 Prolongs Survival 63 Arch Neurol 63 Stent Thrombosis 63 STRIDE PD 63 metastatic GIST 63 mg/m2 dose 63 CALERIE 63 OPT CHF 63 subanalysis 63 Acute Ischemic Stroke 63 APPRAISE 63 neoadjuvant 63 Randomized Phase II 63 Phase Ib II 63 AVOREN 63 pertuzumab 63 Randomized Phase 62 Cholesterol Levels SPARCL 62 Uterine Cancer 62 undergone radical prostatectomy 62 RECIST Response Evaluation Criteria 62 metastatic castration resistant 62 Multicenter Randomized 62 Newly Diagnosed Multiple Myeloma 62 XELOX 62 BRIM3 62 Solid Tumors 62 multicenter randomized controlled 62 CALGB # [002] 62 Relapsing Multiple Sclerosis 62 TORISEL 62 FOLPI 62 Randomized Clinical Trial 62 Velcade bortezomib 62 CHAMPION PCI 62 prospective observational studies 62 Initiated Phase 62 Fondaparinux 62 doxorubicin cyclophosphamide 62 cisplatin gemcitabine 62 BRIM2 62 Unfractionated Heparin 62 chemoradiotherapy 62 standard chemotherapy regimen 62 J Natl Cancer Inst 62 ADVANCE PD 62 Clinical Trials Update 62 Secondary efficacy endpoints 62 Relapsed Multiple Myeloma 62 CARE HF 62 ONTARGET 62 Celecoxib APC trial 62 ACUITY trial 62 irbesartan 62 placebo controlled clinical 62 Ann Oncol 62 Phase III AFFIRM 62 Prospective Randomized Trial 62 TG MV 62 cilostazol 62 Unstable Angina 62 Bivalirudin 62 Decompensated Heart Failure 62 doxorubicin docetaxel 62 Myocardial Infarction Study 62 VIRAMUNE XR 62 underwent surgical resection 62 ACTEMRA TM 62 Neoadjuvant 62 docetaxel chemotherapy 62 FASLODEX 62 nab paclitaxel 61 sorafenib Nexavar 61 trials RCTs 61 Platelet Inhibition 61 Gastrointestinal Cancers Symposium 61 randomized multicenter trial 61 Pharmacokinetic parameters 61 alfa 2a 61 FOLFOX4 61 mcg albinterferon alfa 2b 61 Randomized Controlled Trials 61 candesartan cilexetil 61 See CLINICAL PHARMACOLOGY 61 Doxil ® 61 ritonavir boosted 61 Flu Cy 61 evaluating mipomersen 61 teriflunomide 61 PreCISe 61 recurrent glioblastoma multiforme 61 Response Evaluation Criteria 61 Prostate AdenoCarcinoma Treatment 61 Pooled Analysis 61 PCI ExTRACT TIMI 61 APTIVUS 61 Breast Density 61 pegylated liposomal doxorubicin 61 Group RTOG 61 multicentre randomized 61 prospective multicentre 61 Controlled Trial 61 J Clin Endocrinol Metab 61 Randomized Evaluation 61 APTIVUS r 61 placebo dexamethasone 61 neoadjuvant treatment 61 FOLFIRI 61 Autologous Stem Cell Transplantation 61 plus dexamethasone 61 Phase III VISTA 61 ASCO GI 61 oral FTY# 61 Randomized Study 61 Aortic Stenosis 61 Acute Myocardial Infarction 61 NATRECOR R 61 Perifosine KRX 61 oral rivaroxaban 61 mapatumumab 61 XL# SAR# 61 ongoing Phase 1b 61 Arimidex Tamoxifen Alone 61 BARACLUDE ® 61 ALN HPN 61 Pivotal Phase III 60 chemotherapy gemcitabine 60 ECASS 60 FDG-PET/CT 60 J Clin Oncol 60 GISSI 60 symptomatic BPH 60 Ranolazine 60 stage IIIb IV 60 prospective observational 60 docetaxel Taxotere ® 60 oral diclofenac 60 Metastatic Prostate Cancer 60 dose escalation clinical 60 Femara letrozole 60 ARCOXIA 60 insulin detemir 60 PRE SURGE 60 EORTC 60 viral kinetic 60 Brentuximab Vedotin SGN 60 plus prednisone 60 chemoradiation therapy 60 Dacogen injection 60 angiographic outcomes 60 Multicenter Phase 60 β blockers 60 iniparib BSI 60 Castration Resistant Prostate Cancer 60 Gastric Cancer 60 Acute Coronary Syndromes 60 RE LY 60 sunitinib malate 60 Radiation Therapy Oncology 60 viral kinetics 60 peginterferon alfa 2a 60 PSMA ADC 60 Sorafenib HCC Assessment 60 CIMZIA TM certolizumab pegol 60 Randomized controlled 60 multicenter placebo controlled 60 Tanespimycin 60 tipranavir 60 inhibitor RG# 60 Betaferon ® 60 registrational Phase 60 CLARITY study 60 interferon gamma 1b 60 Adjuvant Chemotherapy 60 BENICAR HCT 60 postintervention 60 Carotid Endarterectomy 60 abacavir lamivudine 60 underwent CABG 60 Chicago Multidisciplinary Symposium 60 Br J Cancer 60 placebo controlled Phase III 60 MGd 60 AVERROES 60 ST Segment Elevation 60 Combination REOLYSIN R 60 MADIT CRT trial 60 Randomized Double blind 60 Prognostic Value 60 CATIE AD 60 morphometric vertebral fractures 60 oxycodone CR 60 PLCO 60 CYPHER Stent 60 Adjuvant Treatment 60 ARIXTRA 60 interferon ribavirin 60 mycophenolate mofetil 60 Lung Cancer Survival 60 pegylated interferon alfa 2b 60 Randomized Clinical Trials 60 mg administered orally 60 multicenter randomized clinical 60 nonrandomized 60 cinacalcet 60 multicenter phase 60 PEGINTRON TM 60 Screening Trial 60 epoetin alpha 60 Advanced Melanoma 60 Dose Escalation 60 BR.# 60 HER2 positive metastatic breast 60 Pemetrexed 60 Multicenter 60 Nymox NX 60 phase IIIb 60 AVN# Phase 60 randomized Phase III 60 postmenopausal osteoporotic women 60 Tumor Response 60 Prostate Lung Colorectal 60 ORAL Sync 60 NSABP 60 CHARISMA trial 60 REMINYL ® 60 metastatic hormone refractory 60 Recurrent Breast Cancer 59 Demonstrates Sustained 59 HBeAg negative patients 59 Digital Mammographic Imaging 59 mITT population 59 mRCC 59 Dose Ranging Study 59 evaluating tivozanib 59 GOUT 59 Renal Cell Carcinoma RCC 59 CIMZIA TM 59 thalidomide Thalomid 59 Peg IFN 59 cancer mCRC 59 fosbretabulin 59 ARB telmisartan 59 Hemodialysis Patients 59 efavirenz EFV 59 CIMZIA ™ 59 ARIXTRA R 59 randomized multicenter 59 Demonstrate Significant 59 ENDEAVOR III 59 Coronary Artery Bypass Graft 59 goserelin 59 PERSEUS 59 Ambulatory Blood Pressure 59 Surgical Treatment 59 estramustine 59 metastatic HRPC 59 boosted protease inhibitor 59 Pivotal Phase 59 neoadjuvant therapy 59 YONDELIS 59 Percutaneous Tibial Nerve Stimulation 59 clinically localized prostate 59 Cardiotoxicity 59 ULORIC 59 liposome injection 59 Meta analyzes 59 PRECiSE 59 aldosterone antagonists 59 EVEREST II 59 carboplatin paclitaxel 59 Late Breaker 59 AZOR 59 Clostridium difficile Infection 59 IFN alfa 59 ANN INTERN MED 59 Faslodex 59 Irinotecan 59 Patients Receiving 59 lexidronam injection 59 Antiplatelet 59 bevacizumab Avastin 59 Poster Discussion 59 Raloxifene Evaluation MORE 59 prospective randomized placebo 59 #mg dosing group 59 AVADO 59 treatment naive genotype 59 TRITON TIMI 59 hormone refractory metastatic prostate 59 ENDEAVOR II 59 Fractional Flow Reserve 59 active comparator 59 Placebo Controlled Study 59 Sibutramine Cardiovascular Outcomes 59 dose escalation phase 59 Society CTOS 59 BMC Musculoskeletal Disorders 59 Parathyroid Hormone 59 Afatinib 59 ZACTIMA 59 Cochrane Database Syst Rev 59 GW# [003] 59 Follicular Lymphoma 59 Nexavar sorafenib 59 anastrazole 59 PROSTVAC TM 59 Carotid Stenting 59 Phase III Clinical Trial 59 neratinib 59 Severe Sepsis 59 Multicenter Study 59 ibandronate 59 randomized controlled clinical trials 59 Double Blind Randomized 59 AIR CF1 59 glatiramer acetate 59 Natalizumab 59 Ovarian Cancer Screening 59 Peginterferon 59 elotuzumab 59 Patient Outcomes 59 desvenlafaxine succinate 59 Multicenter Trial 59 Betaferon R 59 adjuvant radiotherapy 59 tipranavir ritonavir 59 Hepatotoxicity 59 Adjuvant chemotherapy 59 ISEL 59 Eluting Stent 59 somatostatin analog 59 Tarceva TM 59 fluvastatin 59 randomized multicenter Phase III 59 Spine Patient Outcomes 59 Corticosteroid 59 tolvaptan 59 Ozarelix 59 ELACYT 59 Venous Thromboembolism 59 Observational Studies 59 Tipranavir 59 Phase 2b Clinical Trial 59 J Am Coll 59 azilsartan medoxomil 59 Cancer Incidence Mortality 59 Prospective Randomized 59 MERIT ES 59 ER CHOP 59 sipuleucel T 59 papillary renal cell carcinoma 59 REACH Registry 59 TAXUS ATLAS 59 tesmilifene 59 Thromb Haemost 59 SPIRIT FIRST 59 Patients Undergoing 59 randomized controlled Phase 59 Stent Restenosis 59 By JENNIFER LEARN 59 #mg BID [001] 59 Phase III ThermoDox 59 Rheumatoid Arthritis Patients 59 Mg Usa 59 crizotinib PF # 59 TRANSFORMS 59 F FDG PET 59 gemcitabine carboplatin 59 Phase Ib clinical 59 Angiographic 59 recurrent metastatic 59 Topline Results 59 ACCORD Lipid 59 worsening thrombocytopenia 59 TAXUS IV 59 RIO Lipids 59 placebo controlled studies 59 multicenter Phase II 59 meta regression 59 Randomized Controlled 59 Antiviral Activity 59 eplerenone 59 PRoFESS 59 dacarbazine chemotherapy 59 Chronic Heart Failure 59 REYATAZ r 59 prostate cancer HRPC 59 Ann Rheum Dis 59 oral deforolimus 59 Outpatient Setting 58 NICE SUGAR 58 prospective observational cohort 58 enzastaurin 58 Systemic Sclerosis 58 Cardiac Resynchronization 58 complete cytogenetic response 58 ACRIN 58 Delcath Phase III 58 Adjuvant Breast Cancer 58 adalimumab Humira 58 Invasive Breast Cancer 58 cediranib 58 Aflibercept 58 riociguat 58 Edge STudy 58 Bowel Project NSABP 58 DAPT 58 Prostate Screening 58 CTRC AACR San Antonio 58 Antitumor Activity 58 ASCO GU 58 preoperative radiotherapy 58 Demonstrates Efficacy 58 Nephrol Dial Transplant 58 NMIBC 58 phase IIb study 58 adecatumumab 58 atherosclerotic renal artery stenosis 58 brivaracetam 58 Randomized Trials 58 Truvada tablets 58 Insulin Glargine 58 Nebulized 58 Clin Chem 58 Connective Tissue Oncology 58 RE MODEL 58 retrospective cohort 58 retinal vein occlusion 58 prospective nonrandomized 58 DASISION 58 Subgroup analysis 58 Neoadjuvant Chemotherapy 58 Multicenter Automatic Defibrillator Implantation 58 postoperative mortality 58 NCCTG 58 prospective multicenter 58 HCV Protease Inhibitor 58 Phase IIIb clinical 58 GnRH agonists 58 ZOLINZA 58 multicenter Phase 58 resected pancreatic cancer 58 Placebo Controlled Trial 58 Metastatic Renal Cell Carcinoma 58 Echocardiographic 58 invasive candidiasis 58 azacitidine 58 Clinical Outcomes Utilizing Revascularization 58 MERLIN TIMI 58 antiretroviral naïve 58 Valsartan 58 Hepatitis C Genotype 58 KRAS mutations occur 58 Pivotal Clinical Trial 58 telaprevir dosed 58 Ramipril 58 Antihypertensive 58 NATRECOR ® 58 sunitinib 58 AIR2 Trial 58 HIV HCV coinfected 58 Zoledronic Acid 58 ENDEAVOR IV 58 GISSI HF 58 Myelodysplastic Syndromes 58 Phase 1b clinical trials 58 Peginterferon Alfa 2a 58 recurrent GBM 58 trabectedin 58 Intervention Trial GAIT 58 Am J Epidemiol 58 Acute Decompensated Heart Failure 58 paclitaxel eluting stents 58 plus Copegus R 58 Androgen Deprivation Therapy 58 Virologic 58 rosuvastatin Crestor 58 darunavir r 58 remission CR 58 NCT# ClinicalTrials.gov 58 comparator arm 58 Phase Ib Clinical Trial 58 AIR CF2 58 Epirubicin 58 Subgroup Analysis 58 trastuzumab Herceptin ® 58 Kaplan Meier analysis 58 Acute Myocardial 58 blinded randomized placebo controlled 58 Adenoma Prevention 58 motesanib diphosphate 58 treatment naïve genotype 58 pharmacokinetic PK 58 Intervention Effectiveness 58 Screening Trial DMIST 58 Long Term Efficacy 58 null responder HCV 58 tocilizumab 58 Int J Epidemiol 58 p# biomarker 58 Serious Adverse Events 58 LEXIVA r 58 ACE Inhibitor 58 Diabetic Macular Edema 58 Heart Failure Patients 58 coinfected patients 58 metastatic renal cell carcinoma 58 MoxDuo TM IR 58 CHARM Added 58 Arch Surg 58 Intervention Trial 58 phase IIa clinical 58 placebo controlled Phase 58 CTAP# Capsules 58 Pertuzumab 58 Vertebral Fracture 58 Colorectal Cancers 58 lopinavir r arm 58 TASKi2 58 postoperative chemotherapy 58 REALITY Trial 58 J Rheumatol 58 chemoradiation 58 Catheter Ablation 58 Platinol ® 58 Lung Cancers 58 Taxotere R 58 nonmetastatic 58 Chronic Hepatitis C 58 nondiabetic patients 58 Fluorouracil 58 gadobutrol 58 J Clin 58 Infarct 58 AEGR 58 Complicated Skin 58 sorafenib tablets 58 bazedoxifene conjugated estrogens 58 Ibritumomab Tiuxetan 58 Group NCCTG 58 Hematologic 58 prospective randomized multicenter 58 Renal Cell Carcinoma 58 Severe Asthma 58 oral ibandronate 58 metastatic colorectal 58 trastuzumab Herceptin 58 evaluating REVLIMID 58 Dabigatran 58 chemotherapeutic regimen 58 darunavir ritonavir 58 ABC/3TC 58 Pharmacokinetic 58 posaconazole 58 MAGE A3 ASCI 58 BARI 2D 58 MEND CABG 58 FOLFIRI chemotherapy 58 trastuzumab DM1 58 Metastatic Melanoma 58 Tiotropium 58 Heterozygous Familial Hypercholesterolemia 58 Renal Cancer 58 Chronic Myeloid Leukemia 58 R# #mg BID 58 #rd Annual CTRC 58 catheter occlusion 58 EXPAREL ™ 57 Major Adverse Cardiac 57 Clinical Evaluation 57 flurpiridaz F 57 undergoing androgen deprivation 57 AACR San Antonio 57 nonvertebral fractures 57 multicenter randomized Phase III 57 ACE Inhibitors 57 tirofiban 57 abstracts summarizing 57 lipid lowering agents 57 irinotecan cisplatin 57 Prospective Multicenter 57 INCB# [003] 57 SYMMETRY trial 57 J Am Soc 57 Dialysis Outcomes 57 phase IIb clinical 57 underwent resection 57 CANCIDAS 57 ACTIVE W 57 HER2 Positive 57 recurrent glioma 57 everolimus eluting stents 57 multicenter multinational 57 Varespladib 57 Adjuvant Therapy 57 metastatic CRC 57 ACE inhibitor ramipril 57 docetaxel Taxotere R 57 ancrod 57 Stenting Trial 57 Vidaza ® 57 Glucosamine Chondroitin Arthritis 57 -#.# log# copies mL 57 5-FU/LV 57 IFN α 57 Phase #/#a 57 PREZISTA r 57 CCyR 57 Kidney Transplant Patients 57 NO# [002] 57 Resistant Hypertension 57 Schizophrenia Bulletin 57 Fludara 57 neoadjuvant chemotherapy 57 rFVIIa 57 phase Ib 57 evaluable patients 57 CUSTOM II 57 ximelagatran 57 Prognostic Significance 57 Clinical Practice Guideline 57 mg kg Hematide 57 Hedgehog Pathway 57 ORENCIA ® 57 carotid endarterectomy CEA 57 Prostate Cancer Recurrence 57 prospectively defined 57 TMC# r 57 PSADT 57 Amrubicin 57 Meets Primary Endpoint 57 Breast Cancer Recurrence 57 Node Positive 57 Initiate Phase 57 Nat Genet 57 Pharmacodynamic 57 Treated Patients 57 CYT# potent vascular disrupting 57 Alpha Tocopherol Beta Carotene 57 anastrozole 57 RoACTEMRA 57 Lung Cancer Patients 57 Patients Treated With 57 Hormone Receptor Positive 57 Antiviral Therapy 57 Study Evaluating 57 clinical pharmacology studies 57 transthyretin TTR mediated amyloidosis 57 Intravitreal 57 FASEB J. 57 MEK Inhibitor 57 erlotinib Tarceva ® 57 dose melphalan 57 atazanavir ritonavir 57 Cloretazine ® 57 Lung Cancer Trial 57 rosuvastatin #mg 57 Blood Pressure Monitoring 57 colesevelam HCl 57 pyridostigmine 57 Polyp Prevention Trial 57 Antiplatelet Therapy 57 #:# -# [004] 57 Meta Analysis 57 #-# Full Text 57 atorvastatin #mg 57 evaluating carfilzomib 57 DAS# CRP 57 platinum refractory 57 HORIZONS AMI 57 mg BID dose 57 Arimidex anastrozole 57 Kidney Int 57 Chronic Liver Disease 57 COPAXONE R 57 INSPIRE Trial Phase III 57 prucalopride 57 ENDEAVOR clinical 57 NAVISTAR R 57 metastatic lung cancer 57 Novel Oral 57 Clinical Outcomes 57 Evaluation WISE 57 Enoxaparin 57 adjuvant chemotherapy 57 including eniluracil ADH 57 Eur Respir J 57 angiotensin receptor blocker ARB 57 Diabet Med 57 Inflammatory Markers 57 oral ridaforolimus 57 Circulation Heart Failure 57 XIENCE V demonstrated 57 gefitinib Iressa 57 NAMCS 57 AA Amyloidosis 57 acute PAO 57 CT Angiography 57 Degarelix 57 Etanercept 57 Hepatocellular Carcinoma 57 TMC# C# 57 endometrial hyperplasia 57 univariate 57 undergoing Percutaneous Coronary 57 intravesical infusion therapy 57 forodesine 57 Pharmacoeconomics 57 CUSTOM III 57 Pharmacokinetics PK 57 adjuvant trastuzumab 57 CR nPR 57 immunomodulatory agents 57 strontium ranelate 57 metastatic renal cell 57 carotid artery stenting CAS 57 Combination Treatment 57 rt PA 57 BIBW 57 Lipid Lowering Treatment 57 APTIVUS R 57 CROI 57 HORIZONS AMI trial 57 KRAS status 57 Copegus ribavirin 57 adjuvant tamoxifen 57 biochemical relapse 57 multicenter prospective 57 tenofovir emtricitabine 57 JAK Inhibitor 57 Elitek 57 Targretin capsules 57 randomized controlled trials RCTs 57 alvespimycin 57 peg interferon 57 Clinical Antipsychotic Trials 57 Ann Intern Med 57 peginterferon alfa 2b 57 Am J Cardiol 57 Septic Shock 57 iPrEx 57 Localized Prostate Cancer 57 Gemzar ® 57 Recurrent Stroke 57 Prevent Strokes 57 TOHP 57 Heart Failure Therapies 57 II Clinical Trial 57 Hepatitis C Antiviral 57 Lymphoma Patients 57 #F FDG PET CT 57 bevacizumab 57 Immunogenicity 57 Phase III Clinical Trials 57 Temsirolimus 57 oral Xeloda 57 FOLFOX 57 prospective randomized controlled 57 Cutaneous T 57 TTF Therapy 57 Crit Rev 57 ALLHAT 57 retrospective cohort study 57 visceral metastases 57 Dupuytren Contracture 57 paroxetine Paxil 57 pCR 57 Azacitidine 57 infliximab Remicade 57 paclitaxel cisplatin 57 Anticancer Drugs 57 Helicobacter pylori eradication 57 BJU Int 57 prednisone prednisolone 57 LENALIDOMIDE 57 randomized Phase 2b 57 Pneumococcal Vaccine 57 biliary tract cancer 57 methotrexate monotherapy 57 relapsed refractory multiple myeloma 57 Advanced Renal Cell 57 eptifibatide 57 recurrent NSCLC 57 Sapacitabine 57 Myocardial Perfusion Imaging 57 SPIRIT IV 57 Obes Res 57 Eculizumab 57 Second Pivotal Phase 57 Naive Patients 57 Prostate Cancer Progression 57 PREZISTA r arm 57 Nicotine Vaccine 57 Trandolapril 57 Events MACE 57 CALGB # [001] 57 Phase IIA 57 titrated glipizide 57 Hematological 56 Romiplostim 56 Coronary Angiography 56 Myocardial Ischemia 56 CLL8 56 AVASTIN 56 androgen suppression 56 HGPIN 56 VADT 56 refractory CLL 56 EXPLORE Xa 56 Cloretazine 56 Uterine Fibroid Embolization 56 virological response 56 achieved ACR# 56 Cilostazol 56 ACOSOG Z# 56 Clinical Trial Data 56 LUMINATE 56 evaluating Actimmune 56 PACCE trial 56 nadroparin 56 PCWP 56 Intervention Effectiveness CATIE 56 Juvenile Idiopathic Arthritis 56 AIM HIGH 56 Therapeutic Approaches 56 ToGA 56 ENESTnd 56 Liraglutide Effect 56 Therapeutic Arthritis 56 Malignant Melanoma 56 EOquin TM 56 Glufosfamide 56 liver resection 56 bepotastine besilate nasal spray 56 evaluable subjects 56 Thrombolysis 56 aldosterone antagonist 56 FluCAM arm 56 Eur J Neurol 56 pomalidomide 56 IRESSA 56 Sleep Disturbances 56 preclinical efficacy 56 Phase III Trial 56 fluorouracil leucovorin 56 SUTENT ® 56 decitabine 56 Cardiovascular Risk 56 CT Colonography 56 EUS FNA 56 histologically confirmed 56 RTOG 56 peginterferon 56 J Virol 56 CR# vcMMAE 56 Perforomist Inhalation Solution 56 Thromboembolism 56 KRAS mutation 56 dexamethasone Decadron 56 Lp PLA 2 56 PKC# 56 Cardiovascular Interventions 56 ICON7 56 BZA CE 56 octreotide LAR 56 J Am Acad 56 National Surgical Adjuvant 56 relapsing remitting MS RRMS 56 endothelin antagonists 56 MCyR 56 Potent Antiviral Activity 56 #:#-# [031] 56 polyarticular 56 RAPAFLO R 56 Diabetologia 56 multicenter Phase III 56 Eur J Cancer 56 BOXED WARNING 56 Bipolar Disorders 56 unresectable liver cancer 56 ezetimibe simvastatin 56 duplex ultrasonography 56 Therapeutic Advances 56 Cancer Prevention ATBC 56 NSTE ACS 56 Coronary Revascularization 56 Randomized Double Blind 56 ASCO Breast Cancer 56 mCi kg 56 iniparib 56 Refractory Hodgkin Lymphoma 56 Oral Presentations 56 Biomarker Study 56 midstage clinical 56 Percutaneous Coronary Intervention 56 ularitide 56 Urinary Incontinence 56 Novartis Zometa 56 TEMODAL 56 Pirfenidone 56 NEVO 56 dosing cohorts 56 Ischaemic 56 atherothrombotic disease 56 prospectively enrolled 56 Combination therapy 56 randomized trials 56 lymphadenectomy 56 Zenvia Phase III 56 Randomized Comparison 56 Safinamide 56 Decitabine 56 adjuvant endocrine therapy 56 Lung Injury 56 AEG# 56 Hospital Acquired Pneumonia 56 phase Ib clinical 56 multicenter randomized 56 estrogen progestin therapy 56 Phase IIb III 56 Treating Chronic 56 colorectal liver metastases 56 mcg linaclotide 56 low dose dexamethasone 56 invasive aspergillosis 56 dasatinib 56 Cystectomy 56 BOLDER II 56 Clinical Oncology JCO 56 Prednisone Against Refractory 56 basal bolus regimen 56 trastuzumab DM1 T DM1 56 Biological Therapy 56 8mg/kg 56 Clinical Outcome 56 Left Ventricular Dysfunction 56 CRESTOR #mg 56 XIENCE V PROMUS Stent 56 Torisel 56 Regimens 56 FFR guided treatment 56 CAPRIE 56 Combo Stent 56 thetreatment 56 symptomatic carotid stenosis 56 CIN2 + 56 ADAGIO study 56 placebo controlled trials 56 Kahalalide F 56 Pregnancy Registry 56 Renal Insufficiency 56 adriamycin 56 ONTARGET R 56 unstable angina UA 56 trastuzumab emtansine T DM1 56 Catheterization 56 Vaginal Gel 56 ICAAC IDSA 56 Patency